Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 1
2008 1
2009 1
2010 1
2011 2
2012 1
2015 2
2017 2
2018 2
2019 2
2020 1
2022 2
2023 1
2024 1
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.
Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, Ocio EM, Yoon SS, Chu MP, Rodríguez-Otero P, Avivi I, Quijano Cardé NA, Kumar A, Krevvata M, Peterson MR, Di Scala L, Scott E, Hilder B, Vanak J, Banerjee A, Oriol A, Morillo D, Mateos MV; RedirecTT-1 Investigators and Study Group. Cohen YC, et al. Among authors: di scala l. N Engl J Med. 2025 Jan 9;392(2):138-149. doi: 10.1056/NEJMoa2406536. N Engl J Med. 2025. PMID: 39778168 Clinical Trial.
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Sitbon O, et al. Among authors: di scala l. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184. N Engl J Med. 2015. PMID: 26699168 Free article. Clinical Trial.
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.
Sitbon O, Chin KM, Channick RN, Benza RL, Di Scala L, Gaine S, Ghofrani HA, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson VF, Galiè N, Hoeper MM. Sitbon O, et al. Among authors: di scala l. J Heart Lung Transplant. 2020 Apr;39(4):300-309. doi: 10.1016/j.healun.2019.12.013. Epub 2020 Jan 21. J Heart Lung Transplant. 2020. PMID: 32061506 Free article. Clinical Trial.
Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension.
Jansa P, Ambrož D, Aschermann M, Černý V, Dytrych V, Heller S, Kunstýř J, Lindner J, Linhart A, Nižnanský M, Paďour M, Prskavec T, Širanec M, Edwards S, Gressin V, Kuhn M, Di Scala L. Jansa P, et al. Among authors: di scala l. J Clin Med. 2022 Oct 20;11(20):6189. doi: 10.3390/jcm11206189. J Clin Med. 2022. PMID: 36294508 Free PMC article.
Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society Guidelines.
Distler O, Bonderman D, Coghlan JG, Denton CP, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Vonk MC, Di Scala L, Lemarie JC, Perchenet L, Hachulla É. Distler O, et al. Among authors: di scala l. Arthritis Rheumatol. 2024 May;76(5):777-782. doi: 10.1002/art.42791. Epub 2024 Apr 2. Arthritis Rheumatol. 2024. PMID: 38146100 Free article.
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N. Beghetti M, et al. Among authors: di scala l. Eur J Heart Fail. 2019 Mar;21(3):352-359. doi: 10.1002/ejhf.1375. Epub 2019 Jan 11. Eur J Heart Fail. 2019. PMID: 30632656 Free PMC article. Clinical Trial.
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.
Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ. Preston IR, et al. Among authors: di scala l. J Heart Lung Transplant. 2018 Mar;37(3):401-408. doi: 10.1016/j.healun.2017.09.024. Epub 2017 Oct 2. J Heart Lung Transplant. 2018. PMID: 29096938 Clinical Trial.
Correction: Jansa et al. Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension. J. Clin. Med. 2022, 11, 6189.
Jansa P, Ambrož D, Aschermann M, Černý V, Dytrych V, Heller S, Kunstýř J, Lindner J, Linhart A, Nižnanský M, Pad'our M, Prskavec T, Širanec M, Edwards S, Gressin V, Kuhn M, Di Scala L. Jansa P, et al. Among authors: di scala l. J Clin Med. 2023 Jun 9;12(12):3939. doi: 10.3390/jcm12123939. J Clin Med. 2023. PMID: 37373865 Free PMC article.
21 results